Stock Events

Stock Events

Taysha Gene Therapies 

$4.15
0
-$0.2-4.6% Monday 00:46

Statistics

Day High
4.15
Day Low
4.15
52W High
-
52W Low
-
Volume
30
Avg. Volume
-
Mkt Cap
1.14B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2025
Q4 2025
Next
-0.1
-0.09
-0.09
-0.08
Expected EPS
-0.097
Actual EPS
N/A

Financials

-1,071.62%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
16.67MRevenue
-178.6MNet Income

Analyst Ratings

$10.80Average Price Target
The highest estimate is 13.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TSHA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Taysha's focus on gene therapies for CNS disorders.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics is involved in the development of genetically targeted therapies for rare disorders, aligning with Taysha's mission.
Solid Biosciences
SLDB
Mkt Cap419.71M
Solid Biosciences is developing therapies for Duchenne muscular dystrophy, including gene therapies, which puts them in competition with Taysha.
Voyager Therapeutics
VYGR
Mkt Cap259.04M
Voyager Therapeutics specializes in the development of gene therapies for neurodegenerative diseases, directly competing with Taysha's CNS focus.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO, with its focus on AAV gene therapies for a variety of diseases, competes in the same space as Taysha, particularly in CNS disorders.

About

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Show more...
CEO
ISIN
US8776191061

Listings

XNAS
US
TSHA
BOATS
BOATS
TSHA.BOATS

0 Comments

Share your thoughts

FAQ

What is Taysha Gene Therapies stock price today?▼
The current price of TSHA.BOATS is $4.15 USD — it has decreased by -4.6% in the past 24 hours. Watch Taysha Gene Therapies stock price performance more closely on the chart.
What is Taysha Gene Therapies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Taysha Gene Therapies stocks are traded under the ticker TSHA.BOATS.
What is Taysha Gene Therapies market cap?▼
Today Taysha Gene Therapies has the market capitalization of 1.14B
When is the next Taysha Gene Therapies earnings date?▼
Taysha Gene Therapies is going to release the next earnings report on May 20, 2026.
What were Taysha Gene Therapies earnings last quarter?▼
TSHA.BOATS earnings for the last quarter are -0.08 USD per share, whereas the estimation was -0.1 USD resulting in a +16.32% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Taysha Gene Therapies revenue for the last year?▼
Taysha Gene Therapies revenue for the last year amounts to 16.67M USD.
What is Taysha Gene Therapies net income for the last year?▼
TSHA.BOATS net income for the last year is -178.6M USD.
When did Taysha Gene Therapies complete a stock split?▼
Taysha Gene Therapies has not had any recent stock splits.